Cancer BiologybioRxiv
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
W. J. McDaid, L. Wilson, H. Adderley…·A. Malliri
This study compares KRASG12C and KRASG12D mutant NSCLC models, finding that KRASG12D relies more on the PI3K-AKT-mTOR pathway, suggesting tailored combination therapies.
DOI 10.1186/s12943-024-02157-x